Perrigo Co PLC Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
Perrigo Co PLC Stock Forecast and Price Target
Given the average yearlong price target of $40.00 provided by prominent analysts over the past few months, there is a potential upside of approximately 29.87% from the last closing price in April, 2024 for Perrigo Co PLC's stock if it is reached. This estimation is based on a high estimate of $42.00 and a low estimate of $37.00. If you're thinking of investing in PRGO stock, it might be good to look at its rivals too.
29.87% Upside
Perrigo Co PLC Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Perrigo Co PLC's Price has decreased by 100.00%, from $58.45 to $0.00. In the next year, analysts believe that Fair Value will reach $54.23 – an increase of 100.00%. For the next seven years, the forecast is forFair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$726.31 | Buy/Sell | $636.99 | 15.31% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$147.91 | Buy/Sell | $174.55 | 14.93% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$125.78 | Buy/Sell | $130.51 | 10.91% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$26.00 | Buy/Sell | $32.87 | 17.31% |
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
12
|
$394.28 | Buy/Sell | $457.59 | 14.13% |
Perrigo Co PLC Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Perrigo Co PLC's Revenue has decreased by 12.08%, from $5.06B to $4.45B. In the next year, analysts believe that Revenue will reach $5.01B – an increase of 12.65%. For the next seven years, the forecast is forRevenue to grow by 35.79%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$48.93 | Buy/Sell | $58.15 | 12.41% |
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$896.82 | Buy/Sell | $961.26 | 17.08% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$146.50 | Buy/Sell | $220.47 | 51.19% |
.jpg)
Perrigo Co PLC Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, Dividend per Share for Perrigo Co PLC has grown by 15.56%, going from $0.90 to $1.04. In the coming year, analysts are expecting an increase in Dividend per Share, predicting it will reach $1.31 – an increase of 25.96%. Over the next seven years, experts anticipate that Dividend per Share growth for Perrigo Co PLC will be 23.99%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$39.47 | Buy/Sell | $44.86 | 14.01% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$144.41 | Buy/Sell | $245.24 | 48.88% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.25 | Buy/Sell | $11.73 | 6.67% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$237.93 | Buy/Sell | $284.08 | 24.83% |
| CTLT Stock Forecast | Catalent | Hold |
15
|
$55.48 | Buy/Sell | $49.29 | 14.46% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$67.55 | Buy/Sell | $87.92 | 39.16% |
Perrigo Co PLC EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Perrigo Co PLC's EBITDA has seen a drop from $860.50M to $507.20M – a 41.06% decrease. In the next year, analysts are expecting an increase in EBITDA, predicting it will reach $918.54M – an increase of 81.10%. The Perrigo Co PLC forecast is for EBITDA to reach $1.04B or grow by 104.41%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$40.68 | Buy/Sell | $55.60 | 47.98% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$212.04 | Buy/Sell | $315.92 | 83.93% |
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$143.48 | Buy/Sell | $145.00 | 13.60% |
Perrigo Co PLC EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Perrigo Co PLC's EBIT has gone down from $475.70M to $168.60M – a 64.56% drop. For next year, the 3 analysts predict EBIT of $776.76M, which would mean an increase of 360.71%. Over the next seven years, the pros' prediction is EBITof $1.08B, which would mean a seven-year growth forecast of 542.76%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NEOG Stock Forecast | Neogen | Outperform |
16
|
$11.61 | Buy/Sell | $37.00 | 46.43% |
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$40.01 | Buy/Sell | $69.00 | 54.96% |
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$13.78 | Buy/Sell | $29.44 | 146.73% |
Perrigo Co PLC EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Perrigo Co PLC's EPS has decreased by 100.00%, from $4.02 to $0.00. In the next year, analysts believe that EPS will reach $3.73 – an increase of 100.00%. For the next seven years, the forecast is forEPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CORT Stock Forecast | Corcept Therapeutics | Buy |
16
|
$22.95 | Buy/Sell | $35.67 | 65.58% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£15.14 | Buy/Sell | £28.89 | 108.06% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Buy |
14
|
$7.92 | Buy/Sell | $17.83 | 120.96% |
.jpg)